Appropriateness of prostate-specific antigen testing

被引:14
作者
Poteat, HT
Chen, P
Loughlin, KR
Winkelman, JW
Allada, R
Ma'luf, N
Tanasijevic, MJ
Bates, DW
机构
[1] Brigham & Womens Hosp, Div Gen Med, Dept Med, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Clin Labs, Boston, MA 02115 USA
[3] Brigham & Womens Hosp, Ctr Appl Med Informat Syst, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Div Urol, Boston, MA 02115 USA
[5] Med Scientists, Boston, MA USA
关键词
utilization; prostate-specific antigen; benchmark; indicators; appropriateness; guidelines; test ordering; evidence-based medicine;
D O I
10.1309/E11X-491Y-GUJH-EGGF
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
We established criteria for appropriate use of the prostate-specific antigen? (PSA) assay and used them to evaluate PSA test utilization nr 1 tertiary care institution. During a 6-month period 2,330 PSA results were reported for outpatients and 95 for inpatients. We reviewed medical records for a random sample of 338 outpatient results (14.51%) and all 95 inpatient results, of which 21% (71/338) of outpatient and 17% (16/95) of inpatient results were inappropriate according ro our rest utilization criteria. Among outpatients, 52% of rests were done for screening and 19% for monitoring for cancer recurrence. For inpatients, workup for cancer (53/95 [56%]) was the most frequent indication for testing and screening the second (24/95 [25%]). Of tests failing the criteria, 66 (76%) of 87 resulted from excessively frequent and age-inappropriate screening. We assessed the potential effect on clinical outcome if these tests were not performed. Of the 87 rests considered inappropriate, only I test result influenced clinical management for patients younger than 75 years. By instituting simple limits on age and frequency, we estimate that 74% (64/87) of the inappropriate tests could have been eliminated.
引用
收藏
页码:421 / 428
页数:8
相关论文
共 46 条
[1]   Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: Results of a randomized, double-blind, placebo-controlled clinical trial [J].
Andriole, GL ;
Guess, HA ;
Epstein, JI ;
Wise, H ;
Kadmon, D ;
Crawford, ED ;
Hudson, P ;
Jackson, CL ;
Romas, NA ;
Patterson, L ;
Cook, TJ ;
Waldstreicher, J .
UROLOGY, 1998, 52 (02) :195-201
[2]   CANCER STATISTICS, 1993 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (01) :7-26
[3]   Prediction of capsular perforation and seminal vesicle invasion in prostate cancer [J].
Bostwick, DG ;
Qian, JQ ;
Bergstralh, E ;
Dundore, P ;
Dugan, J ;
Myers, RP ;
Oesterling, JE .
JOURNAL OF UROLOGY, 1996, 155 (04) :1361-1367
[4]   COMPARATIVE-STUDY OF THE CLINICAL USEFULNESS OF PROSTATE SPECIFIC ANTIGEN AND PROSTATIC ACID-PHOSPHATASE IN PROSTATIC DISEASE [J].
BUAMAH, PK ;
JOHNSON, P ;
SKILLEN, AW .
BRITISH JOURNAL OF UROLOGY, 1988, 62 (06) :581-583
[5]   Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer [J].
Carter, HB ;
Epstein, JI ;
Chan, DW ;
Fozard, JL ;
Pearson, JD .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (18) :1456-1460
[6]  
*CLIN LAB IMPR AM, 1993, FED REGISTER, V58, P39860
[7]  
COOKE RR, 1992, NEW ZEAL MED J, V105, P345
[8]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[9]  
DEMERS RY, 1994, IN VIVO, V8, P429
[10]   The definition and preoperative prediction of clinically insignificant prostate cancer [J].
Dugan, JA ;
Bostwick, DG ;
Myers, RP ;
Qian, JQ ;
Bergstralh, EJ ;
Oesterling, JE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 275 (04) :288-294